NO20083572L - Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer - Google Patents

Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer

Info

Publication number
NO20083572L
NO20083572L NO20083572A NO20083572A NO20083572L NO 20083572 L NO20083572 L NO 20083572L NO 20083572 A NO20083572 A NO 20083572A NO 20083572 A NO20083572 A NO 20083572A NO 20083572 L NO20083572 L NO 20083572L
Authority
NO
Norway
Prior art keywords
thiazole compounds
pkb
protein kinase
inhibitors
treatment
Prior art date
Application number
NO20083572A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew Tasker
Chester Chenguang Yuan
Christopher H Fotsch
Nianhe Han
Aiwen Li
Qingyian Liu
Matthew Lee
Qingping Zeng
John Gordon Allen
Matthew Paul Bourbeau
Celina Dominguez
Fang-Tsao Hong
Xin Huang
James Thomas Rider
Seifu Tadesse
Vellarkad Narayana
Xianghong Wang
Kurt E Weiler
George Erich Wohlhieter
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20083572L publication Critical patent/NO20083572L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
NO20083572A 2006-01-18 2008-08-18 Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer NO20083572L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18
PCT/US2007/000871 WO2007084391A2 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b ( pkb) inhibitors

Publications (1)

Publication Number Publication Date
NO20083572L true NO20083572L (no) 2008-10-17

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083572A NO20083572L (no) 2006-01-18 2008-08-18 Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer

Country Status (21)

Country Link
US (2) US7514566B2 (US08084479-20111227-C00234.png)
EP (1) EP1981884B1 (US08084479-20111227-C00234.png)
JP (1) JP5199885B2 (US08084479-20111227-C00234.png)
KR (1) KR20080091369A (US08084479-20111227-C00234.png)
CN (1) CN101421265A (US08084479-20111227-C00234.png)
AR (1) AR059064A1 (US08084479-20111227-C00234.png)
AU (1) AU2007207743B2 (US08084479-20111227-C00234.png)
BR (1) BRPI0706621A2 (US08084479-20111227-C00234.png)
CA (1) CA2636077C (US08084479-20111227-C00234.png)
CR (1) CR10211A (US08084479-20111227-C00234.png)
EA (1) EA200801716A1 (US08084479-20111227-C00234.png)
ES (1) ES2389062T3 (US08084479-20111227-C00234.png)
IL (1) IL192751A0 (US08084479-20111227-C00234.png)
MY (1) MY149143A (US08084479-20111227-C00234.png)
NO (1) NO20083572L (US08084479-20111227-C00234.png)
PE (1) PE20071114A1 (US08084479-20111227-C00234.png)
TW (1) TW200738657A (US08084479-20111227-C00234.png)
UA (1) UA91895C2 (US08084479-20111227-C00234.png)
UY (1) UY30098A1 (US08084479-20111227-C00234.png)
WO (1) WO2007084391A2 (US08084479-20111227-C00234.png)
ZA (1) ZA200806386B (US08084479-20111227-C00234.png)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400689T3 (es) 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
KR20090113326A (ko) * 2007-02-13 2009-10-29 쉐링 코포레이션 작용 선택적 알파2c 아드레날린성 수용체 효능제
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2011525929A (ja) * 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Akt活性の阻害剤
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
DK3135672T3 (da) * 2008-10-10 2020-05-04 Vm Discovery Inc Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
ES2544452T3 (es) * 2008-12-19 2015-08-31 Genentech, Inc. Compuestos heterocíclicos y métodos de uso
WO2010083246A1 (en) * 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
WO2010151689A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
US8835450B2 (en) * 2009-10-08 2014-09-16 Glaxosmithkline Llc Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
MX2012004140A (es) * 2009-10-08 2012-09-07 Glaxosmithkline Llc Combinacion.
US20120202822A1 (en) * 2009-10-12 2012-08-09 Kurtis Earl Bachman Combination
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MY173795A (en) 2009-11-05 2020-02-24 Incozen Therapeutics Pvt Ltd Novel benzopyran kinase modulators
WO2011115071A1 (ja) * 2010-03-15 2011-09-22 国立大学法人広島大学 チエノピリジン誘導体及びその製造方法、並びにそれを用いた有機半導体デバイス
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法
EP2558459B1 (en) * 2010-04-16 2014-01-22 Abbvie Inc. Phthalazin-(2h)-one inhibitors of kinases
US20130102605A1 (en) * 2010-04-23 2013-04-25 Peng Liang Inhibitors of akt activity
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
DK2870157T3 (da) 2012-07-04 2017-11-06 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
EP2958902B1 (en) 2013-02-19 2017-11-15 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
KR20150127249A (ko) * 2013-03-13 2015-11-16 보스톤 바이오메디칼, 인크. 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
PT3068393T (pt) 2013-11-11 2022-06-14 Amgen Inc Terapia de combinação, incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
KR20170122799A (ko) * 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AR107840A1 (es) * 2016-03-10 2018-06-13 Astrazeneca Ab INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
CR20190424A (es) 2017-03-30 2019-11-04 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
JP2022542392A (ja) * 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Kif18a阻害剤としてのピリジン誘導体
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (US08084479-20111227-C00234.png) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
WO1996016650A1 (fr) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
JP2002518380A (ja) 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU3487500A (en) 1999-02-08 2000-08-25 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd p38MAPキナーゼ阻害剤
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
US7495018B2 (en) * 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003029248A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
JP2005526720A (ja) 2002-02-13 2005-09-08 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
CA2475299A1 (en) * 2002-02-28 2003-09-04 Patrizio Mattei Thiazole derivatives as npy receptor antagonists
MY156407A (en) * 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
KR20050088283A (ko) 2002-10-30 2005-09-05 버텍스 파마슈티칼스 인코포레이티드 Rock 및 기타 단백질 키나제의 억제제로서 유용한조성물
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AU2004267094A1 (en) * 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
AU2004272599A1 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
BRPI0506749A (pt) 2004-01-12 2007-05-22 Applied Research Systems derivados de tiazol e uso dos mesmos
WO2005073226A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole, leur preparation et leur application en therapeutique
DK1709018T3 (da) * 2004-01-16 2011-11-14 Sanofi Sa Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
RS50595B (sr) 2004-03-23 2010-05-07 Pfizer Products Incorporated Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
AU2005247871A1 (en) * 2004-04-27 2005-12-08 Research Development Foundation Antagonism of TGF-beta superfamily receptor signaling
AU2005245962A1 (en) * 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
US7410988B2 (en) 2004-08-13 2008-08-12 Genentech, Inc. 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
ES2400689T3 (es) * 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2006093247A1 (ja) * 2005-02-28 2006-09-08 Japan Tobacco Inc. Syk阻害活性を有する新規なアミノピリジン化合物
MX2007015863A (es) * 2005-06-17 2008-04-02 Apogee Biotechnology Corp Inhibidores de esfingosina cinasa.
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
JP5064237B2 (ja) 2005-12-09 2012-10-31 Meiji Seikaファルマ株式会社 リンコマイシン誘導体およびこれを有効成分とする抗菌剤
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
AR059021A1 (es) 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
JP2009523751A (ja) 2006-01-18 2009-06-25 エフ.ホフマン−ラ ロシュ アーゲー Mdm2阻害剤としてのシス−4,5−ビアリール−2−ヘテロサイクリック−イミダゾリン
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CA2636077A1 (en) 2007-07-26
US7514566B2 (en) 2009-04-07
AR059064A1 (es) 2008-03-12
KR20080091369A (ko) 2008-10-10
CN101421265A (zh) 2009-04-29
WO2007084391A3 (en) 2008-03-20
US20090270445A1 (en) 2009-10-29
ES2389062T3 (es) 2012-10-22
BRPI0706621A2 (pt) 2011-04-05
EA200801716A1 (ru) 2009-04-28
MY149143A (en) 2013-07-15
AU2007207743A1 (en) 2007-07-26
ZA200806386B (en) 2009-11-25
JP5199885B2 (ja) 2013-05-15
EP1981884B1 (en) 2012-06-13
US8084479B2 (en) 2011-12-27
UY30098A1 (es) 2007-10-31
CR10211A (es) 2008-10-03
JP2009525960A (ja) 2009-07-16
US20070173506A1 (en) 2007-07-26
CA2636077C (en) 2012-01-03
AU2007207743B2 (en) 2010-07-08
IL192751A0 (en) 2009-02-11
TW200738657A (en) 2007-10-16
EP1981884A2 (en) 2008-10-22
PE20071114A1 (es) 2008-01-10
UA91895C2 (en) 2010-09-10
WO2007084391A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
NO20083690L (no) Hydantoin baserte kinase-inhibitorer
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
WO2009011850A3 (en) Novel therapeutic compounds
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
WO2006093547A3 (en) Novel lipoxygenase inhibitors
WO2011056985A3 (en) Substituted heterocyclic compounds
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application